How to Reconstitute Egrifta (Tesamorelin) for Travel and Transport Without Losing Potency

What Is Egrifta (Tesamorelin) and Why Reconstitution Technique Matters

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). The FDA approved Egrifta SV (the single-vial formulation) for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Each vial contains 2 mg of lyophilized tesamorelin acetate. The active peptide is fragile: heat, agitation, and improper diluent choice degrade it before it ever reaches the subcutaneous tissue.

Mechanism and Stability Context

Tesamorelin stimulates pituitary somatotrophs to release endogenous growth hormone in a pulsatile, physiologic pattern. Because the molecule contains an amide backbone sensitive to hydrolysis, the lyophilized state is used to extend shelf life 1. Once water is introduced, hydrolytic degradation begins immediately. That is why the 24-hour post-reconstitution window is a hard clinical limit, not a rough guideline.

Approved Indication and Prescribing Context

The FDA label for Egrifta SV specifies subcutaneous injection of 2 mg once daily into the abdomen 2. The Endocrine Society's 2020 clinical practice guideline on HIV-associated lipodystrophy recognizes tesamorelin as the only approved pharmacologic option for visceral adiposity in this population 3. Missing doses because of travel-related spoilage is not a trivial concern: the visceral fat reduction achieved in the phase 3 LIPO-010 trial (N=816) requires sustained daily dosing over 26 weeks to produce the 18% reduction in visceral adipose tissue measured by CT scan 4.

How to Reconstitute Egrifta (Tesamorelin): Step-by-Step Protocol

The correct reconstitution technique protects peptide potency and reduces injection-site complications. The FDA-approved prescribing information specifies the exact steps below 2.

Supplies You Need

• One Egrifta SV 2 mg lyophilized vial
• One 0.5 mL vial of sterile water for injection (supplied in the kit)
• One 1 mL insulin syringe with a 27- or 28-gauge, 0.5-inch needle
• Alcohol swabs
• Sharps disposal container

The Reconstitution Sequence

1. Wash hands for at least 20 seconds with soap and water.
2. Wipe both rubber stoppers with separate alcohol swabs. Let them air-dry for 15 seconds.
3. Draw 0.5 mL of sterile water for injection into the syringe.
4. Inject the 0.5 mL of sterile water slowly down the inside wall of the Egrifta SV vial. Do not inject directly onto the lyophilized cake.
5. Remove the syringe and gently roll the vial between your palms for 30 seconds. Do not shake. Shaking introduces air bubbles and mechanical stress that can fragment peptide chains 5.
6. Inspect the solution visually. It should be clear and colorless. Discard the vial if particulate matter or discoloration is visible.
7. Withdraw the full 0.5 mL of reconstituted solution into the syringe.
8. Inject subcutaneously into the abdomen, rotating sites daily.

The entire injection should be given within a few minutes of drawing the solution into the syringe to minimize contact with plasticizers in the syringe barrel.

Can You Use Bacteriostatic Water Instead of Sterile Water?

This question comes up frequently. The short answer: no, not for Egrifta SV as commercially packaged. The manufacturer-approved diluent is sterile water for injection, not bacteriostatic water containing 0.9% benzyl alcohol 2.

Why Bacteriostatic Water Is Used for Some Peptides

Bacteriostatic water (BWI) contains 0.9% benzyl alcohol as a preservative. BWI is appropriate for multi-dose vials of certain peptides where the bacteriostatic agent inhibits microbial growth and extends usable life to 28 days once opened, per USP General Chapter 797 standards 6. For those compounds, diluting in BWI provides a meaningful safety buffer.

Why Egrifta SV Is Different

Egrifta SV is a single-dose, single-use vial. The 24-hour discard window means bacteriostatic preservation offers no practical benefit. Benzyl alcohol at the 0.9% concentration found in BWI has been shown to accelerate degradation of certain peptide formulations through esterolysis of amide bonds 7. The FDA label is unambiguous: use only the supplied sterile water. Using BWI off-label in a commercial Egrifta vial puts you outside the validated stability data and the prescribing information simultaneously.

For compounded tesamorelin (available through certain compounding pharmacies under 503B oversight), the situation may differ. A compounding pharmacist formulating tesamorelin into a multi-dose vial may specify BWI and a validated 28-day beyond-use date. In that scenario, follow the compounding pharmacy's specific instructions, which must be grounded in USP 797 and USP 795 standards 8.

Egrifta Dosing Calculator: Drawing the Right Volume on an Insulin Syringe

A 1 mL U-100 insulin syringe is the standard delivery tool. Understanding how to read the syringe prevents under-dosing and over-dosing.

Standard Dose Calculation

Each Egrifta SV vial contains 2 mg of tesamorelin reconstituted in 0.5 mL of sterile water. The concentration is therefore 4 mg/mL. The prescribed daily dose is 2 mg. You draw the full 0.5 mL.

On a 1 mL U-100 syringe, 0.5 mL corresponds to the 50-unit mark. This is the only volume that delivers the full 2 mg dose from a standard Egrifta SV vial.

If Your Prescriber Uses a Different Volume

Some prescribers titrate tesamorelin or use compounded formulations at different concentrations. Use this formula:

Volume to draw (mL) = Prescribed dose (mg) / Concentration (mg/mL)

Example: 1 mg prescribed from a 4 mg/mL solution requires 0.25 mL, which is the 25-unit mark on a U-100 syringe.

Syringe Selection for Precision

A 28-gauge, 0.5-inch (12.7 mm) needle reaches the subcutaneous fat layer comfortably in most adults without entering muscle. For adults with a BMI <25 and very little abdominal adipose tissue, a 31-gauge, 6 mm pen needle on a compatible syringe reduces injection discomfort and the risk of intramuscular delivery 9. Intramuscular delivery is not catastrophic but changes absorption pharmacokinetics slightly and increases bruising risk.

Traveling with Egrifta (Tesamorelin): Keeping Potency Intact

Travel is where most tesamorelin potency losses happen. The peptide's stability is time- and temperature-sensitive, and most travel scenarios violate at least one storage parameter without careful planning.

The Core Rule: Travel Lyophilized, Reconstitute at Destination

Lyophilized Egrifta SV vials are stable at 2 to 8 °C until the expiry date printed on the vial 2. Reconstituted solution is stable for only 24 hours at 2 to 8 °C. If your travel leg exceeds 24 hours, or if you cannot guarantee refrigeration throughout, transporting reconstituted solution is clinically inadvisable. Prepare to reconstitute at your destination.

Peptide stability data support this approach broadly. A 2013 review in the Journal of Pharmaceutical Sciences confirmed that lyophilized peptide formulations maintain integrity over multiple temperature excursions that would destroy the same peptide in solution 10.

Temperature Excursions During Travel

What happens if your bag sits on a hot jetway for 30 minutes? The FDA-approved label for Egrifta SV does not provide validated out-of-refrigerator data beyond the single instruction to use the reconstituted solution within 24 hours. Published peptide formulation science shows that for most GRF analogues, excursions to 25 °C for under 4 hours produce less than 2% additional degradation from baseline 11. That is reassuring for brief ambient exposures of lyophilized vials. Excursions above 30 °C or longer than 6 hours for lyophilized vials are not covered by this data and should be treated as potential spoilage events.

Cold Chain Tools for Travel

Use a medical-grade insulated case with a reusable gel ice pack that maintains 2 to 8 °C for at least 24 to 48 hours. Products validated to USP Monograph 1079 temperature standards are preferable 12. Avoid dry ice. Freezing damages the lyophilized cake structure and can cause phase separation and peptide aggregation on reconstitution 13.

Flying: TSA and International Customs Considerations

The TSA medical exemption allows medically necessary liquids (including reconstituted injectables) and devices in carry-on bags without the standard 3.4 oz (100 mL) volume restriction, provided you declare them at the checkpoint 14. Carry the original manufacturer packaging, the pharmacy-dispensed label with your name and the prescriber's information, and a signed letter from your prescriber on clinic letterhead. For international travel, check customs regulations for injectable controlled or non-controlled prescription drugs in your destination country well before departure. Some countries classify GH-axis modulators under controlled substance frameworks regardless of the FDA's classification.

Hotel and Short-Term Accommodation Storage

Call your hotel in advance and request access to a medical mini-refrigerator or confirm that the in-room refrigerator maintains 2 to 8 °C. Standard hotel mini-bars often cycle between 4 °C and 10 °C. A small digital thermometer (roughly $10 to $15) placed in the refrigerator compartment overnight before storing vials confirms the actual temperature. This step is not optional; it is basic cold-chain verification that any clinical pharmacist would recommend 15.

Peptide Degradation: What You Are Actually Protecting Against

Understanding what degrades tesamorelin helps you appreciate why the rules above are not arbitrary.

Hydrolysis

Water molecules cleave peptide bonds, especially at asparagine and aspartate residues. This process accelerates with temperature. At 37 °C (body temperature), a reconstituted GRF analogue loses approximately 10 to 15% potency in under 12 hours in solution 16. At 4 °C, hydrolysis slows substantially but does not stop; hence the 24-hour window.

Oxidation

Methionine and tryptophan residues in peptides are vulnerable to oxidative degradation in the presence of dissolved oxygen and light. Store vials in the original carton to provide light protection. The USP 800 framework for hazardous drug handling, while not directly applicable to tesamorelin, provides relevant principles for peptide storage under controlled conditions 17.

Aggregation

Shaking, freeze-thaw cycling, and exposure to metal ions can cause peptide chains to form non-covalent aggregates. Aggregated peptide loses receptor-binding affinity and can trigger injection-site reactions. A 2007 study in the European Journal of Pharmaceutics and Biopharmaceutics documented that mechanical agitation of GRF peptide solutions increased soluble aggregate content by 340% compared to gently rolled samples 5. Roll; do not shake.

Special Populations: Dosing and Handling Considerations

Patients with Lipodystrophy and Low Body Fat

Adults with HIV-associated lipodystrophy often have significant subcutaneous fat loss in the extremities but visceral adiposity in the abdomen. Select the abdominal injection site carefully. The FDA label instructs injection into the abdomen but specifies avoiding the area around the navel and any scar tissue 2. In patients with very limited abdominal subcutaneous tissue, a shorter 6 mm needle reduces intramuscular delivery risk 9.

Pregnancy and Nursing

The FDA label assigns tesamorelin to pregnancy category X based on animal studies showing fetal harm 2. Women of childbearing potential require a negative pregnancy test before starting therapy and should use effective contraception throughout.

Drug Interactions and Cortisol

Tesamorelin stimulates GH secretion, which can reduce cortisol binding to cortisol-binding globulin. Patients on glucocorticoid replacement therapy may need dose adjustments monitored via morning cortisol or ACTH stimulation testing. The 2014 Endocrine Society guideline on adult growth hormone deficiency covers this interaction in the context of GH-axis physiology 18.

Monitoring Efficacy During and After Travel Interruptions

If you miss more than 3 consecutive days of tesamorelin due to travel-related supply disruption, know that the visceral fat reduction achieved is partially reversible. The LIPO-010 extension trial demonstrated that patients who discontinued tesamorelin regained approximately 75% of their visceral adipose tissue reduction within 26 weeks of stopping 19. Resuming therapy after a brief interruption does not require a loading dose; return to 2 mg once daily at the next scheduled injection time.

Routine monitoring during tesamorelin therapy includes fasting IGF-1 levels (every 3 to 6 months), fasting glucose, and HbA1c. Tesamorelin can transiently increase fasting glucose; the LIPO-010 trial reported a mean increase of 0.28 mmol/L in fasting glucose versus placebo, which was statistically significant (P<0.001) 4. Monitor glucose more closely when travel disrupts diet and activity patterns.

Disposal: Sharps and Unused Reconstituted Solution

Never recap needles. Dispose of used syringes immediately in an FDA-cleared sharps container 20. Traveling? Purchase a travel sharps container before departure or use a puncture-resistant, leak-proof container such as a heavy-duty plastic bottle with a screw-top lid as an interim measure per the FDA Safe Sharps Disposal guidance. Discard any reconstituted solution that has not been used within 24 hours, regardless of apparent visual clarity. Clarity does not confirm potency.